Search results
Results from the WOW.Com Content Network
Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, particularly with regard to postprandial hyperglycemia. The intake of a single dose before a meal containing complex carbohydrates clearly suppresses the glucose spike and may decrease the postprandial hyperglycemia ...
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [1] [2] It is used together with a diabetic diet and exercise. [1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth.
However, he says you can often lower your risk of side effects by staying well hydrated, eating smaller meals, and limiting processed foods, high-fat foods, and refined carbohydrates.
The group found that people taking the GLP-1 medications had a lower risk of a number of health conditions, including Alzheimer’s disease and dementia, addiction, seizures, blood-clotting ...
The study consisted of 48 participants (34 women, 14 men), with half the participants receiving a weekly low-dose injection of semaglutide, while the other half received a placebo.
In September 2019, a version that can be taken orally (Rybelsus) was approved for medical use in the United States, [70] [71] and in the European Union in April 2020. [ 18 ] In June 2021, a higher-dose version for injectable use sold under the brand name Wegovy was approved by the FDA as an anti-obesity medication for long-term weight ...
She began taking the medication in 2023 after her health care provider prescribed it over concern she was becoming prediabetic. Her A1C came down, and she reached her goal weight of 145 pounds.
Compared to people using insulin, patients taking GLP-1 agonists showed significant risk reduction in esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer, as well as meningioma and multiple myeloma. Kidney cancers showed an increased risk with GLP-1 treatment relative to those treated with metformin. [27]